ClinicalTrials.gg
RecruitingNCT05324332Updated Sep 22, 2025

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

An interventional study of 68Ga-P16-093 and 68Ga-PSMA-11 in Prostate Cancer, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. gallium 68 PSMA-11 · Prostatic Neoplasms.

Planned enrollment
23rd of 49
50 · median 50
Started
2022
with 4 others
No phase
4 of 49
2 open now
Primary completion
2025-01
later than 2 of 10 live
Registered
35th of 49
by date
Lead sponsor
2 of 49
Peking Union Medical College Hospital

Among the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, this one is the 23rd largest by planned enrollment, is one of 5 that started in 2022, is one of 4 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 35th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About gallium 68 PSMA-11

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gallium 68 PSMA-11 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

Read the detailed description

Prostate cancer (PC) is one of the most common malignancies worldwide in men, with persistently high numbers dying from this disease. Due to low levels of glycolysis in prostate cancer cell, the uses of 18F-FDG PET/CT to detect prostate cancer and its metastases are limited. Prostate specific membrane antigen (PSMA), as known as folate hydrolase I or glutamate carboxypeptidase II, is overexpressed on the cells of prostatic adenocarcinoma. Various low molecular weight radiopharmaceuticals targeting PSMA such as PSMA-11, PSMA-617 for 68Ga-labeling have been developed. 68Ga-PSMA PET/CT has demonstrated desirable sensitivity and specificity in the detection of prostate cancer lesions, which can find many micro lesions that cannot be identified by CT, MRI and bone scan. 68Ga-P16-093, a novel radiopharmaceutical modified based on 68Ga-PSMA-11, with the urea fragment of a conjugate that employs the HBED-CC chelator for labeling with 68Ga(III). The HBED-based chelating ligand binds the 68Ga3+ ion with high affinity in a pseudo-octahedral N2O4 coordination sphere by its two phenolate O, two amino-acetate carboxylate O, and two amino N donor atoms. This pilot study was prospectively designed to evaluate the diagnostic performance of 68Ga-P16-093 compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed untreated primary prostate cancer patients;
  • 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week;
  • signed written consent.

Exclusion criteria

Exclusion Criteria:

  • known allergy against PSMA;
  • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scan

    Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.

    Drug: 68Ga-P16-093 · Drug: 68Ga-PSMA-11

Interventions

  • Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.

    Also known as: 68Ga-P16-093 injection

  • DrugGallium 68 PSMA-11Studies of Gallium 68 PSMA-11Gallium 68 PSMA-11 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.

    Also known as: 68Ga-PSMA-11 injection

06

What researchers measure

Primary outcomes

  1. Tumor detection rate

    comparing the number of tumor detected by 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. standardized uptake value (SUV) of tumor

    comparing the SUVmax of tumor derived from 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. PSMA expression and SUV

    Correlation between PSMA immunoreactive score and SUVmax of tumor

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang J, Li L, Chen J, Wang R, Xiang J, Peng X, Wang Y, Luo Y, Zhu L, Kung HF, Zhou Z, Xiao Y, Zhu Z. [68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11. Eur J Nucl Med Mol Imaging. 2026 Apr;53(5):3064-3073. doi: 10.1007/s00259-025-07687-0. Epub 2025 Dec 10. PubMed 41366119 ↗
  • Wang G, Li L, Zhu M, Zang J, Wang J, Wang R, Yan W, Zhu L, Kung HF, Zhu Z. A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3126-3136. doi: 10.1007/s00259-023-06283-4. Epub 2023 May 26. PubMed 37233785 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jan 2025, 32 months.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 32 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2022
First posted
Apr 12, 2022
StartActual
Apr 15, 2022
Primary completionActual
Jan 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05324332
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Apr 15, 2022
Primary completion
Jan 1, 2025
Completion
Dec 31, 2025 (estimated)
Last update
Sep 22, 2025

Study contacts

Zhaohui Zhu, MD
Contact
13611093752@163.com
86-13611093752
Guochang Wang, MD
Contact
guochang1007@163.com
86-18516822732
Zhaohui Zhu, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 68 Ga-P16-093 · Gallium 68 PSMA-11

Start the discussion